NeoGenomics, Inc. (NEO): Price and Financial Metrics
NEO Price/Volume Stats
| Current price | $17.03 | 52-week high | $20.54 |
| Prev. close | $17.02 | 52-week low | $6.00 |
| Day low | $16.75 | Volume | 487,992 |
| Day high | $17.28 | Avg. volume | 1,092,962 |
| 50-day MA | $16.59 | Dividend yield | N/A |
| 200-day MA | $12.44 | Market Cap | 2.17B |
NEO Stock Price Chart Interactive Chart >
NEO POWR Grades
- Growth is the dimension where NEO ranks best; there it ranks ahead of 92.08% of US stocks.
- NEO's strongest trending metric is Growth; it's been moving up over the last 179 days.
- NEO ranks lowest in Momentum; there it ranks in the 4th percentile.
NEO Stock Summary
- With a price/sales ratio of 4.31, NEOGENOMICS INC has a higher such ratio than 75.76% of stocks in our set.
- In terms of twelve month growth in earnings before interest and taxes, NEOGENOMICS INC is reporting a growth rate of 236.96%; that's higher than 93.89% of US stocks.
- The volatility of NEOGENOMICS INC's share price is greater than that of 83.82% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to NEOGENOMICS INC, a group of peers worth examining would be TMCI, EVER, WTT, DGLY, and RKDA.
- Visit NEO's SEC page to see the company's official filings. To visit the company's web site, go to www.neogenomics.com.
NEO Valuation Summary
- In comparison to the median Healthcare stock, NEO's EV/EBIT ratio is 255% lower, now standing at -18.6.
- NEO's EV/EBIT ratio has moved down 2.6 over the prior 234 months.
Below are key valuation metrics over time for NEO.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| NEO | 2023-05-23 | 4.3 | 2.3 | -18.2 | -18.6 |
| NEO | 2023-05-22 | 4.4 | 2.4 | -18.6 | -18.9 |
| NEO | 2023-05-19 | 4.3 | 2.3 | -18.2 | -18.5 |
| NEO | 2023-05-18 | 4.3 | 2.4 | -18.3 | -18.7 |
| NEO | 2023-05-17 | 4.4 | 2.4 | -18.6 | -18.9 |
| NEO | 2023-05-16 | 4.3 | 2.3 | -18.2 | -18.5 |
NEO Growth Metrics
- Its 4 year net income to common stockholders growth rate is now at 112.24%.
- Its 4 year net cashflow from operations growth rate is now at -18.8%.
- Its 2 year net cashflow from operations growth rate is now at -660.72%.
The table below shows NEO's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-12-31 | 509.728 | -65.993 | -144.25 |
| 2022-09-30 | 496.755 | -82.084 | -163.322 |
| 2022-06-30 | 489.313 | -73.579 | -146.818 |
| 2022-03-31 | 485.965 | -57.973 | -35.642 |
| 2021-12-31 | 484.329 | -26.723 | -8.347 |
| 2021-09-30 | 484.594 | -0.962 | 48.828 |
NEO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- NEO has a Quality Grade of C, ranking ahead of 30.23% of graded US stocks.
- NEO's asset turnover comes in at 0.366 -- ranking 397th of 561 Business Services stocks.
- MSFT, VRNS, and SGRP are the stocks whose asset turnover ratios are most correlated with NEO.
The table below shows NEO's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.366 | 0.422 | 0.085 |
| 2021-03-31 | 0.414 | 0.399 | -0.033 |
| 2020-12-31 | 0.490 | 0.418 | -0.014 |
| 2020-09-30 | 0.508 | 0.419 | -0.033 |
| 2020-06-30 | 0.522 | 0.433 | -0.042 |
| 2020-03-31 | 0.589 | 0.468 | 0.016 |
NEO Price Target
For more insight on analysts targets of NEO, see our NEO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $56.80 | Average Broker Recommendation | 1.25 (Strong Buy) |
NeoGenomics, Inc. (NEO) Company Bio
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company was founded in 2001 and is based in Fort Myers, Florida.
Latest NEO News From Around the Web
Below are the latest news stories about NEOGENOMICS INC that investors may wish to consider to help them evaluate NEO as an investment opportunity.
Zacks.com featured highlights include First Watch Restaurant, NeoGenomics and Universal Stainless & Alloy ProductsFirst Watch Restaurant, NeoGenomics and Universal Stainless & Alloy Products are part of the Zacks Screen of the Week article. |
3 Best Breakout Stocks to Invest in for Superlative ReturnsFirst Watch Restaurant Group (FWRG), NeoGenomics (NEO), and Universal Stainless & Alloy Products (USAP) have been selected as the breakout stocks for today. |
4 big analyst picks: Alcon upgraded to Outperform after Q1 beat | Pro RecapBaird upgraded Alcon (NYSE:ALC) to Outperform from Neutral and raised its price target to $90.00 from $75.00 following Q1 earnings. Shares jumped more than 7% pre-market today after the company reported its Q1 results, with EPS of $0.70 and revenue of $2.3 billion beating the consensus estimates. BTIG upgraded NeoGenomics (NASDAQ:NEO) to Buy from Neutral with a price target of $25.00, noting it was impressed by the change in underlying growth at the company since the new management team has taken over. |
NeoGenomics Reports Q1 Topline Growth, Lifts Annual Guidance, Shares SoarNeoGenomics Inc (NASDAQ: NEO) reported Q1 revenues of $137.22 million, +17.1% Y/Y beating the consensus of $126.39 million. Clinical Services revenue of $115 million increases 16% Y/Y. Clinical test volume increased by 7%. The average revenue per clinical test increased by 8% to $402. Pharma Services revenue increased by 22% to $22 million. Adjusted EBITDA loss was $(7) million compared to $(19) million in the first quarter of 2022. Adjusted Net Loss was $(12) million compared to $(25) million a |
NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue EstimatesNeoGenomics (NEO) delivered earnings and revenue surprises of 35.71% and 8.64%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? |
NEO Price Returns
| 1-mo | 15.69% |
| 3-mo | -1.79% |
| 6-mo | 46.56% |
| 1-year | 102.26% |
| 3-year | -36.19% |
| 5-year | 35.81% |
| YTD | 84.31% |
| 2022 | -72.92% |
| 2021 | -36.63% |
| 2020 | 84.07% |
| 2019 | 131.96% |
| 2018 | 42.33% |
Continue Researching NEO
Here are a few links from around the web to help you further your research on Neogenomics Inc's stock as an investment opportunity:Neogenomics Inc (NEO) Stock Price | Nasdaq
Neogenomics Inc (NEO) Stock Quote, History and News - Yahoo Finance
Neogenomics Inc (NEO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...